Werewolf Therapeutics, Inc. (HOWL): Results of Operations and Financial Condition
Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates Watertown, Mass., July 31, 2026 (GLOBE NEWSWIRE) – Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pione
How this was made
The 30-second read
Why it matters
Traders can update models for cash runway, burn trajectory, and pipeline monetization. The strategic alternatives process increases optionality but also uncertainty, which can affect valuation multiples and event-driven positioning.
Market read
The release combines a monetization event ($21.0m collaboration revenue) with a sharp cash decline and a stated runway into Q2 2027, plus a second-half strategic alternatives catalyst.
What to watch
G&A rose materially year over year ($7.7m vs $4.4m), which could worsen burn even if R&D decreased ($6.2m vs $13.1m). Also, the strategic alternatives process is only described at a high level, so the market may discount the probability and timing of any transaction.
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
The company reported $21.0 million of collaboration revenue tied to the JZP898 program sale and net income of $3.7 million, while cash and cash equivalents declined to $22.0 million from $46.5 million as of March 31, 2026. Werewolf repaid all amounts owed to K2, has no defined timeline for its strategic-alternatives process, and expects its current operating plan to fund operations only into the second quarter of 2027.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenue, three months ended June 30, 2026GAAP | $ 21,000 (amounts in thousands) | – | – |
| Research and development expenses, three months ended June 30, 2026GAAP | $ 6,162 (amounts in thousands) | – | – |
| General and administrative expenses, three months ended June 30, 2026GAAP | $ 7,680 (amounts in thousands) | – | – |
| Total operating expenses, three months ended June 30, 2026GAAP | $ 13,842 (amounts in thousands) | – | – |
| Operating income (loss), three months ended June 30, 2026GAAP | $ 7,158 (amounts in thousands) | – | – |
| Other expense, three months ended June 30, 2026GAAP | $ (3,488) (amounts in thousands) | – | – |
| Net income (loss), three months ended June 30, 2026GAAP | $ 3,670 (amounts in thousands) | – | – |
| Net income (loss) per common share, basic and diluted, three months ended June 30, 2026GAAP | $ 0.08 | – | – |
| Weighted-average common shares outstanding, basic and diluted, three months ended June 30, 2026GAAP | 48,597,534 | – | – |
| Collaboration revenue, six months ended June 30, 2026GAAP | $ 21,000 (amounts in thousands) | – | – |
| Research and development expenses, six months ended June 30, 2026GAAP | $ 14,343 (amounts in thousands) | – | – |
| General and administrative expenses, six months ended June 30, 2026GAAP | $ 12,770 (amounts in thousands) | – | – |
| Total operating expenses, six months ended June 30, 2026GAAP | $ 27,113 (amounts in thousands) | – | – |
| Operating income (loss), six months ended June 30, 2026GAAP | $ (6,113) (amounts in thousands) | – | – |
| Other expense, six months ended June 30, 2026GAAP | $ (3,749) (amounts in thousands) | – | – |
| Net income (loss), six months ended June 30, 2026GAAP | $ (9,862) (amounts in thousands) | – | – |
| Net income (loss) per common share, basic and diluted, six months ended June 30, 2026GAAP | $ (0.20) | – | – |
| Weighted-average common shares outstanding, basic and diluted, six months ended June 30, 2026GAAP | 48,597,177 | – | – |
| Cash and cash equivalents as of June 30, 2026GAAP | $ 21,987 (amounts in thousands) | – | – |
| Working capital as of June 30, 2026GAAP | $ 15,029 (amounts in thousands) | – | – |
| Total assets as of June 30, 2026GAAP | $ 24,155 (amounts in thousands) | – | – |
| Total notes payable, net of discount and issuance costs, as of June 30, 2026GAAP | $ — (amounts in thousands) | – | – |
| Total stockholders’ equity as of June 30, 2026GAAP | $ 16,292 (amounts in thousands) | – | – |
| Cash and cash equivalents as of December 31, 2025GAAP | $ 57,050 (amounts in thousands) | – | – |
| Working capital as of December 31, 2025GAAP | $ 22,438 (amounts in thousands) | – | – |
| Total assets as of December 31, 2025GAAP | $ 69,396 (amounts in thousands) | – | – |
| Total notes payable, net of discount and issuance costs, as of December 31, 2025GAAP | $ 28,236 (amounts in thousands) | – | – |
| Total stockholders’ equity as of December 31, 2025GAAP | $ 24,805 (amounts in thousands) | – | – |
into the second quarter of 2027 outlook
- NoteBased on its current operating plan, the Company expects to be able to fund its operations into the second quarter of 2027.
- NoteIn the second half of the year, we expect to provide additional updates on the strategic alternatives process and data updates on our clinical trials of WTX-124 and WTX-330.
What drove it
- Collaboration revenue of $21.0 million consisted of revenue recognized related to the agreement to sell the JZP898 program to Jazz Pharmaceuticals Ireland Limited.
- The asset purchase agreement with Jazz and repayment of the K2 loan included a $21.0 million payment to Werewolf.
- Werewolf is exploring options for continued development of its INDUKINE and INDUCER platforms and programs.
- The company expects to provide data updates on clinical trials of WTX-124 and WTX-330 in the second half of the year.
Concerns
- No collaboration revenue was recognized during the second quarter of 2025, and the reported second-quarter 2026 collaboration revenue was tied to the JZP898 program sale.
- Cash and cash equivalents were $22.0 million as of June 30, 2026, compared to $46.5 million as of March 31, 2026.
- The company does not have a defined timeline for the exploration and evaluation of strategic alternatives and cannot confirm that the process will result in a strategic alternative being announced or consummated.
- The company identifies its ability to continue as a going concern among the risks and uncertainties cited in the release.
What to watch
- Additional updates on the strategic alternatives process in the second half of the year.
- Data updates from clinical trials of WTX-124 and WTX-330 in the second half of the year.
- Execution against the expectation to fund operations into the second quarter of 2027.
- Further development plans for the INDUKINE and INDUCER platforms and programs following the Jazz transaction.
Balance sheet and cash flow
- Cash and cash equivalents were $22.0 million as of June 30, 2026, compared to $46.5 million as of March 31, 2026.
- Cash and cash equivalents were $ 21,987 (amounts in thousands) as of June 30, 2026, compared with $ 57,050 (amounts in thousands) as of December 31, 2025.
- Working capital was $ 15,029 (amounts in thousands) as of June 30, 2026, compared with $ 22,438 (amounts in thousands) as of December 31, 2025.
- Total notes payable, net of discount and issuance costs, was $ — (amounts in thousands) as of June 30, 2026, compared with $ 28,236 (amounts in thousands) as of December 31, 2025.
- The company repaid all amounts owed under its loan and security agreement with K2 HealthVentures LLC.
Analysis
Werewolf reported collaboration revenue of $21.0 million in the second quarter of 2026, with the release specifying that it consisted of revenue recognized from the agreement to sell the JZP898 program to Jazz Pharmaceuticals Ireland Limited. No collaboration revenue was recognized during the second quarter of 2025. This transaction-related revenue drove operating income of $ 7,158 (amounts in thousands) and net income of $ 3,670 (amounts in thousands), compared with an operating loss of $ (17,542) (amounts in thousands) and net loss of $ (17,982) (amounts in thousands) in the prior-year quarter.
The expense profile changed materially year over year. Research and development expense was $ 6,162 (amounts in thousands), compared with $ 13,143 (amounts in thousands), while general and administrative expense was $ 7,680 (amounts in thousands), compared with $ 4,399 (amounts in thousands). Total operating expenses were $ 13,842 (amounts in thousands), compared with $ 17,542 (amounts in thousands). Other expense was $ (3,488) (amounts in thousands), compared with $ (440) (amounts in thousands), limiting reported quarterly net income to $ 3,670 (amounts in thousands).
Liquidity and balance-sheet changes remain central to the report. Cash and cash equivalents were $22.0 million as of June 30, 2026, compared to $46.5 million as of March 31, 2026. The balance sheet reported $ 21,987 (amounts in thousands) of cash and cash equivalents, $ 15,029 (amounts in thousands) of working capital, and $ 16,292 (amounts in thousands) of total stockholders’ equity at June 30, 2026. The company repaid all amounts owed under its K2 loan and security agreement, and total notes payable, net of discount and issuance costs, was $ — (amounts in thousands) at June 30, 2026, versus $ 28,236 (amounts in thousands) at December 31, 2025.
Management stated that, based on its current operating plan, it expects to fund operations into the second quarter of 2027. It also expects strategic-alternatives and WTX-124 and WTX-330 clinical-data updates in the second half of the year. The release states that the strategic-alternatives process has no defined timeline and offers no assurance that it will produce an announced or consummated transaction. Accordingly, the transaction-related collaboration revenue, the remaining cash position, clinical updates, and the strategic process are the principal reported items for investors to monitor.
Management, verbatim
In the second quarter of 2026, as previously announced, Werewolf entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited (“Jazz”) with respect to the JZP898 program previously licensed to Jazz, and repaid all amounts owed under its loan and security agreement with K2 HealthVentures LLC (“K2”). Together, these transactions, which included a $21.0 million payment to Werewolf, enabled the Company to explore multiple options for the continued development of its INDUKINE and INDUCER platforms and programs.
Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf
In the second half of the year, we expect to provide additional updates on the strategic alternatives process that is being run with assistance from our exclusive financial advisor, Piper Sandler & Co. (“Piper Sandler”), as well as data updates on our clinical trials of WTX-124 and WTX-330.
Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf
Not in the filing
stated, not guessed- Gross profit and gross margin
- Revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Prior-quarter revenue, expenses, operating income, net income, EPS, and weighted-average share comparisons
- Printed year-over-year and quarter-over-quarter percentage changes for financial metrics
- Operating cash flow
- Free cash flow
- Cash-flow statement and capital-expenditure figures
- Share repurchases
- Dividends
- Segment revenue disclosure
- Non-GAAP financial measures
- CFO commentary
- Prior outlook for guidance comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This SEC 8-K includes Werewolf’s Q2 2026 financial results and corporate updates, including the JZP898 asset purchase agreement and repayment of its K2 loan.
Ticker impact
Werewolf reported Q2 2026 results and disclosed a Jazz asset purchase for JZP898 plus repayment of its K2 loan, alongside a reduced cash balance.
Likely near-term volatility driven by runway math and strategic-alternatives expectations, with direction dependent on how investors value the JZP898 monetization versus ongoing burn.
The filing provides specific cash figures ($22.0m vs $46.5m), recognizes $21.0m collaboration revenue tied to the JZP898 sale, and states funding into Q2 2027. It also flags a strategic alternatives process for the second half of 2026, which can re-rate the equity but lacks deal specifics in this release.
Market effects
Biopharma investors may reassess small-cap immunotherapy platform risk when monetization of a licensed program is paired with a strategic alternatives process.
Limited, primarily affects US small-cap biotech sentiment.
Limited, as the disclosed transaction is company-specific and not a broad regulatory or macro catalyst.
Counterpoint
The cash runway statement may not fully de-risk dilution risk if trial timelines slip or if strategic alternatives do not produce value-enhancing outcomes.
Key entities
- companyWerewolf Therapeutics, Inc.
Nasdaq-listed biopharmaceutical company reporting Q2 2026 results and disclosing JZP898 sale to Jazz plus K2 loan repayment.
- counterpartyJazz Pharmaceuticals Ireland Limited
Buyer of the JZP898 program under an asset purchase agreement referenced in the filing.
- lenderK2 HealthVentures LLC
Counterparty for the loan and security agreement that Werewolf repaid in connection with the transactions.
- advisorPiper Sandler & Co.
Exclusive financial advisor assisting the strategic alternatives process referenced for the second half of 2026.
